Phio Pharmaceuticals(US:PHIO) TMX Newsfile·2026-01-15 13:45Core Insights - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to combat cancer [1][4] - The company is currently conducting a Phase 1b clinical trial for its lead compound PH-762, aimed at treating various forms of skin cancer, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4] Company Presentation - CEO Robert Bitterman will present an update on the INTASYL siRNA technology and the ongoing clinical trial for PH-762 on January 22, 2026, at 1:45 PM ET [2] - Investors are invited to register for one-on-one meetings with the CEO during the conference from January 21 to January 22, 2026 [2] Company Background - Phio Pharmaceuticals is advancing its INTASYL technology, which is designed to enhance the immune system's ability to target and kill cancer cells [4] - The lead clinical program, PH-762, specifically silences the PD-1 gene, which is implicated in skin cancer [4]